Media Articles Related to Provenge (Sipuleucel-T)
International agreement on MRI-scans 'likely to change how we detect prostate cancer'
Source: MRI / PET / Ultrasound News From Medical News Today [2015.10.02]
International radiological bodies* have agreed on a standard for how doctors evaluate MRI to confirm a diagnosis of prostate cancer.
New prostate cancer treatments could target metabolism
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.09.30]
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S.
Risk factors for prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2015.09.30]
New research suggests that age, race and family history are the biggest risk factors for a man to develop prostate cancer, although high blood pressure, high cholesterol, vitamin D deficiency...
Fewer, larger radiotherapy doses prove effective for prostate cancer patients
Source: Prostate / Prostate Cancer News From Medical News Today [2015.09.28]
Giving fewer but higher doses of radiotherapy, is as effective at treating prostate cancer as giving lower doses for a longer period, according to new research* presented at the 2015 European...
Study raises questions about androgen deprivation therapy for certain prostate cancer cases
Source: Cardiovascular / Cardiology News From Medical News Today [2015.09.23]
Among men with unfavorable-risk prostate cancer and moderate or severe co-existing illness, long-term follow-up finds that radiation therapy alone vs radiation therapy and androgen deprivation...
Published Studies Related to Provenge (Sipuleucel-T)
Building on sipuleucel-T for immunologic treatment of castration-resistant
prostate cancer. 
phosphatase/granulocyte-macrophage colony-stimulating factor antigen... CONCLUSIONS: There is potential to build on sipuleucel-T to further advance
Sipuleucel-T immune parameters correlate with survival: an analysis of the
randomized phase 3 clinical trials in men with castration-resistant prostate
responses to overall survival (OS)... CONCLUSION: Sipuleucel-T broadly engages the immune system by activating APCs ex
Cancer immunotherapy: sipuleucel-T and beyond. [2011.08]
In April 2010, sipuleucel-T became the first anticancer vaccine approved by the United States Food and Drug Administration. Different from the traditional chemotherapy agents that produce widespread cytotoxicity to kill tumor cells, anticancer vaccines and immunotherapies focus on empowering the immune system to overcome the tumor.
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. [2011.07.01]
CONCLUSIONS: No significant difference in time to BF could be shown. The finding of increased PSADT in the sipuleucel-T arm is consistent with its biologic activity in ADPC. Long-term follow-up will be necessary to determine if clinically important events, such as distant failure, are affected by therapy. Treatment was generally well tolerated.
Sipuleucel-T: in metastatic castration-resistant prostate cancer. [2011.01.01]
Sipuleucel-T is an autologous active cellular immunotherapy used in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC)... infusion-related events, such as chills and fever) generally occurred within the first day after administration of sipuleucel-T and resolved within 2 days.
Clinical Trials Related to Provenge (Sipuleucel-T)
Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC [Not yet recruiting]
This clinical trial studies the effect of radium-223 when added to sipuleucel-T for treating
castrate-resistant prostate cancer that has spread to the bone. Sipuleucel-T is an
autologous cellular immunotherapy designed to stimulate an immune response against prostate
cancer. It has been suggested that the immune response may be strengthened by radiation
therapy. Therefore this study is testing whether radium-223 added to sipuleucel-T increases
the immune response and anti-tumor effect against prostate cancer.
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer [Completed]
The main purpose of this study is to determine whether ADT started before or after
sipuleucel-T leads to a better immune system response. This study will also evaluate the
safety of sipuleucel-T treatment, immune system responses over time, the characteristics of
sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.
Sipuleucel-T Manufacturing Demonstration Study [Active, not recruiting]
To demonstrate that sipuleucel-T can be successfully manufactured for subjects with
metastatic castrate resistant prostate cancer (mCRPC) at a European manufacturing facility.
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer [Recruiting]
- Sipuleucel-T is a new treatment for advanced stage prostate cancer. It takes cells from a
person with prostate cancer and treats them in the laboratory. Then it returns the cells to
the person to help the immune system fight the cancer. Sipuleucel-T may be combined with the
drug CT-011 to boost its ability to kill cancer cells. The chemotherapy drug
cyclophosphamide will also be given, either before or after the cells are collected at the
start of the treatment.
- To test the effectiveness of Sipuleucel-T, CT-011, and cyclophosphamide for prostate
- Men at least 18 years of age who have advanced prostate cancer.
- Participants will be screened with a medical history, physical exam, blood and urine
tests, and imaging studies.
- This study has two parts, with different participants in each part. All participants
will be monitored with frequent blood tests and imaging studies.
- Part I:
- Participants will provide cells for the Sipuleucel-T treatment three times. The first
time will be 3 days before the chemotherapy. The second time will be 10 days after
chemotherapy. The third time will be 24 days after chemotherapy.
- Participants will have one dose of cyclophosphamide the day before the first dose of
- Participants will have Sipuleucel-T about 3 days after each cell donation.
- Part II:
- Participants will be in three groups: Sipuleucel-T given alone, given with CT-011, or
given with both cyclophosphamide and CT-011.
- Participants will provide cells for the Sipuleucel-T treatment three times, as in Part
- Participants will have Sipuleucel-T about 3 days after each cell donation, and will
receive treatment with the other drugs as directed by the study doctors.
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402) [Active, not recruiting]
This study is being conducted to examine the immune response generated by sipuleucel-T in
subjects previously treated with sipuleucel-T in the androgen dependent setting. The study
will also assess the safety of receiving up to 3 additional infusions of sipuleucel-T. This
is an open-label, uncontrolled, multicenter study, conducted in up to 14 clinical trial
sites. The anticipated duration of the study is approximately 6 years.
Reports of Suspected Provenge (Sipuleucel-T) Side Effects
Disease Progression (31),
Dehydration (26), more >>